Adage Capital Partners
MNPR icon

Adage Capital Partners’s Monopar Therapeutics MNPR Stock Holding History

Adage Capital Partners’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Sell
209,195
-100,000
-32% -$6.19M 0.03% 506
2026
Q1 		$16.9M Sell
309,195
-330,272
-52% -$20M 0.03% 543
2025
Q4 		$41.8M Sell
639,467
-19,728
-3% -$1.61M 0.06% 293
2025
Q3 		$53.8M Buy
659,195
+60,000
+10% +$2.68M 0.09% 226
2025
Q2 		$21.4M Hold
599,195
– – 0.04% 436
2025
Q1 		$21.8M Hold
599,195
– – 0.04% 392
2024
Q4 		$13.2M Buy
+599,195
New +$10.1M 0.02% 542

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Adage Capital Partners's MNPR Position: Q2 2026 in Review

Adage Capital Partners reduced its Monopar Therapeutics (MNPR) stake by 32% in Q2 2026, selling an estimated $6.19M and leaving 209,195 shares worth $19.4M. The position accounts for 0.03% of the portfolio, ranked #506.

Adage Capital Partners first reported a position in MNPR in Q4 2024 and has held it in 7 quarters since. The position peaked at $53.8M in Q3 2025. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Adage Capital Partners held 209,195 shares of Monopar Therapeutics worth $19.4M as of Q2 2026.
  • Adage Capital Partners sold 100,000 Monopar Therapeutics shares in Q2 2026, an estimated $6.19M.
  • Monopar Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #506 holding.
  • Adage Capital Partners first reported a position in Monopar Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Adage Capital Partners's Monopar Therapeutics position peaked at $53.8M in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.